Policy / Pricing NHS risks missing out on independent prescriber benefits PharmaphorumGaps in support could undermine a wave of new independent prescribers entering the NHS and a push for more community-based care, warns a new report.Policy / PricingRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaphorum Gaps in support could undermine a wave of new independent prescribers entering the NHS and a push for more community-based care, warns a new report. Policy / PricingRead full story Post navigation Previous: Novartis-backed Sidewinder collects $137M series B to strike at difficult-to-treat tumorsNext: Roche sticks with C4T, adding up to $1B for molecular glue partnership Related Stories Policy / Pricing Mid-cap biotechs join Trump’s latest round of drug pricing deals pharminent September 1, 2026 Policy / Pricing MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones pharminent August 27, 2026 Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026